CALI.CN - FinCanna Capital Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.28
-0.00 (-1.75%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.28
Open0.28
Bid0.28 x 0
Ask0.29 x 0
Day's Range0.28 - 0.29
52 Week Range0.23 - 3.00
Volume82,376
Avg. Volume182,653
Market Cap27.521M
Beta0.72
PE Ratio (TTM)N/A
EPS (TTM)-0.31
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire5 days ago

    FinCanna Capital Welcomes Rosy Mondin to its Board of Advisors

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (FNNZF) a royalty company for the U.S. licensed medical cannabis industry is pleased to announce the appointment of Ms. Rosy Mondin to its Board of Advisors. Ms. Mondin is a leading advocate for the legalization of adult use cannabis in Canada and is the first woman to hold the role of CEO in a publicly traded company in the cannabis sector. Specializing in corporate law, Ms. Mondin served as strategic advisor for several companies involved in the processing, distribution, and safe use of medical cannabis.

  • GlobeNewswire12 days ago

    FinCanna Capital Corp. Issues a Letter to its Shareholders

    As most of you may know, FinCanna is a Royalty Company for the licensed medical cannabis sector with a focus on California, which is the most populous state in the U.S., the fifth largest economy in the world and the largest cannabis market in North America.

  • GlobeNewswirelast month

    FinCanna Advances Second Tranche of Capital to Refined Resin Technologies Inc.

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (FNNZF) a royalty company for the US licensed medical cannabis industry, has advanced US$1 million, the second tranche of capital, to its investee company Refined Resin Technologies Inc. (“Refined Resin”) of Oakland, California. Refined Resin is a cannabinoid research and extraction company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain. This capital is the second in a series of tranches to be advanced as Refined Resin implements its three-phase development strategy to operationalize its legally zoned, large, state-of-the-art medical cannabis extraction laboratory.

  • GlobeNewswirelast month

    FinCanna Advances First Tranche of Capital to Refined Resin Technologies Inc.

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (FNNZF) a royalty company for the US licensed medical cannabis industry, has advanced US $1.25 million, the initial tranche of capital, to its investee company Refined Resin Technologies Inc. (“Refined Resin”) of Oakland, California. Refined Resin is retrofitting a legally zoned, large, state-of-the-art medical cannabis extraction laboratory, in Oakland, California and is targeting to be in operation by late 2018 or early 2019. Refined Resin's principals have extensive experience in extraction, manufacturing and business operations and intend to be premier producers of bulk quantities of THC (tetrahydrocannabinol) distillate and various high-value concentrates produced via hydrocarbon-based solvent extraction.

  • GlobeNewswire2 months ago

    FinCanna Advances Second Tranche of Capital to ezGreen Compliance to Drive Continued Growth

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (FNNZF) a royalty company for the U.S. licensed medical cannabis industry, announces that it has advanced US$ 1 million to its investee company ezGreen Compliance (“ezGreen”) which offers a state-of-the-art enterprise compliance and point-of-sale (POS) software solution for licensed medical cannabis dispensaries and cultivators. FinCanna has now advanced US$ 1.75 million of the US$ 3 million to be funded under the Royalty Agreement, which entitles FinCanna to a perpetual royalty equal to 10% of consolidated gross revenues of Green Compliance, subject to certain buy-back options.

  • GlobeNewswire2 months ago

    FinCanna Capital Welcomes John Campbell to its Advisory Board

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (FNNZF) a royalty company for the U.S. licensed medical cannabis industry, is pleased to announce the appointment of Mr. John Campbell to its Advisory Board. Mr. Campbell has over 35 years of experience in the investment industry, and currently serves as Chairman and CFO of TriView Capital, one of Canada’s largest Exempt Market Dealers. Mr. Campbell was formerly a Managing Director of private equity firm Second City Capital.

  • GlobeNewswire2 months ago

    FinCanna Investment, CTI Executes Exclusive Manufacturing and Distribution Agreement with Phoenix Tears for its THC Based Products in California

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (FNNZF) a royalty company for the U.S. licensed medical cannabis industry, reports that Cultivation Technologies Inc. (CTI) its first investment in California, announced today that it has executed an agreement with Phoenix Tears LLC, to be the exclusive manufacturer and distributer of official Phoenix Tears THC based products in California. Since its inception in 2010, Phoenix Tears—through its cannabis research and formulations—has supported more than 200,000 individuals through its brand and products which now resonate globally.

  • GlobeNewswire2 months ago

    FinCanna Executes & Increases Royalty Payments Under Agreement with Refined Resin Technologies Inc. a California Based Cannabis and Extraction Company

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (FNNZF) a royalty company for the U.S. licensed medical cannabis industry, has executed an Expanded Royalty Agreement with Refined Resin Technologies Inc. (“Refined Resin”) formerly known as Gram Co Holdings LLC, of Oakland, California. Refined Resin is a cannabinoid research and refinery company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain. FinCanna will fund US$3 million in tranches to complete the original Royalty Agreement transaction that was previously announced under a binding term sheet in February 2018.  In return, FinCanna will receive a tiered corporate royalty, ranging from 14% to 5.0% of Refined Resin’s annual revenues, based upon agreed upon benchmarks.

  • GlobeNewswire3 months ago

    FinCanna Closes Second and Final Tranche of Oversubscribed Private Placement for Total Proceeds of $6.8 million

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) a royalty company for the U.S. licensed medical cannabis industry, announces that it has closed its second and final tranche of the oversubscribed private placement previously announced on June 15 and upsized on June 18, 27 and 29, 2018.  The Company issued an additional 2,270,422 Units at a price of $0.30 per unit for gross proceeds of $681,128. Each Unit consists of one common share of FinCanna and one common share purchase warrant.  Each full warrant will be exercisable to acquire one common share of FinCanna at an exercise price of $0.45 for 24 months from the date of the closing of the Private Placement.

  • GlobeNewswire3 months ago

    FinCanna Closes Oversubscribed Private Placement for $6.1 Million

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) a royalty company for the U.S. licensed medical cannabis industry, announces that it has closed its oversubscribed private placement previously announced on June 15 and upsized on June 18, 27 and 29, 2018.  The Company issued 20,396,535 Units at a price of $0.30 per unit for gross proceeds of $6,118,961. The Company anticipates some additional funds to be received within the week and will close these additional units at that time. Each Unit consists of one common share of FinCanna and one common share purchase warrant.  Each full warrant will be exercisable to acquire one common share of FinCanna at an exercise price of $0.45 for 24 months from the date of the closing of the Private Placement.

  • GlobeNewswire3 months ago

    FinCanna Increases Private Placement to $6.1 Million

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) a royalty company for the U.S. licensed medical cannabis industry is pleased to announce that following higher than anticipated demand the Company has increased the size of its previously announced non-brokered private placement financing. Initially announced at $3 million and subsequently raised to $5 million and $5.5 million, the Company has now increased its non-brokered private placement offering to $6.1 million. Each Unit will consist of one common share of FinCanna and one common share purchase warrant.

  • GlobeNewswire3 months ago

    Coverage Initiated for FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) via NetworkNewsWire

    FinCanna Capital Corp. (CSE:CALI) (FNNZF), a royalty company for the U.S. licensed medical cannabis industry, announces it has engaged the corporate communications expertise of NetworkNewsWire ("NNW"). FinCanna Capital is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

  • GlobeNewswire3 months ago

    FinCanna Increases Private Placement to $5.5 Million

    FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) a royalty company for the U.S. licensed medical cannabis industry is pleased to announce that following higher than anticipated demand the Company has increased the size of its previously announced non-brokered private placement financing. Initially announced at $3 million and subsequently raised to $5 million, the Company has now increased its non-brokered private placement offering to $5.5 million. Each Unit will consist of one common share of FinCanna and one common share purchase warrant.